T
Thomas Bieber
Researcher at University of Bonn
Publications - 5
Citations - 1670
Thomas Bieber is an academic researcher from University of Bonn. The author has contributed to research in topics: Atopic dermatitis & Precision medicine. The author has an hindex of 5, co-authored 5 publications receiving 1229 citations. Previous affiliations of Thomas Bieber include University of St. Gallen.
Papers
More filters
Journal ArticleDOI
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson,Thomas Bieber,Emma Guttman-Yassky,Lisa A. Beck,Andrew Blauvelt,Michael J. Cork,Jonathan I. Silverberg,Mette Deleuran,Yoko Kataoka,Jean-Philippe Lacour,Külli Kingo,Margitta Worm,Margitta Worm,Yves Poulin,Andreas Wollenberg,Yuhwen Soo,Neil M.H. Graham,Gianluca Pirozzi,Bolanle Akinlade,Heribert Staudinger,Vera Mastey,Laurent Eckert,Abhijit Gadkari,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +25 more
TL;DR: Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Journal ArticleDOI
Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?
Thomas Bieber,Thomas Bieber,Angelo Massimiliano D'Erme,Cezmi A. Akdis,Claudia Traidl-Hoffmann,Roger Lauener,Georg Schäppi,Peter Schmid-Grendelmeier +7 more
TL;DR: A systems biology approach merging the numerous clinical phenotypes with robust biomarkers will be needed to best exploit their potential significance for the future molecular taxonomy of AD.
Journal ArticleDOI
The cradle of IgE autoreactivity in atopic eczema lies in early infancy.
Nadine Mothes,Bodo Niggemann,Claudia Jenneck,Tobias Hagemann,Stephan Weidinger,Thomas Bieber,Rudolf Valenta,Natalija Novak +7 more
Journal ArticleDOI
Off-label prescriptions for atopic dermatitis in Europe.
Thomas Bieber,B. Straeter +1 more
TL;DR: A clinical algorithm for the off‐label prescription of systemic immunosuppressants in AD is provided, the apparent dilemma between approval and guidelines is discussed, and practical rules to be considered in the context of off-label prescription are suggested.
Journal ArticleDOI
How to Define Atopic Dermatitis
TL;DR: There is an urgent need for biomarker discovery further supporting the clinical diagnostic criteria as well as the precision medicine approach on a global level.